GT200300287A - Complejos de e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino]quinazolin-6-il}alil)acetamida,suprocedimiento de produccion y uso - Google Patents

Complejos de e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino]quinazolin-6-il}alil)acetamida,suprocedimiento de produccion y uso

Info

Publication number
GT200300287A
GT200300287A GT200300287A GT200300287A GT200300287A GT 200300287 A GT200300287 A GT 200300287A GT 200300287 A GT200300287 A GT 200300287A GT 200300287 A GT200300287 A GT 200300287A GT 200300287 A GT200300287 A GT 200300287A
Authority
GT
Guatemala
Prior art keywords
suprocediment
methylpiridin
iloxi
metoxi
alil
Prior art date
Application number
GT200300287A
Other languages
English (en)
Inventor
Zheng Jane Li
Jason Albert Leonard
Andrew Vincent Trask
John Charles Kath
Daniel Tyler Richter
Carl Brian
Joel Morris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GT200300287A publication Critical patent/GT200300287A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL COMPUESTO QUE SE MUESTRA EN EL RESUMEN Y QUE ES DE UTILIDAD EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS TALES COMO EL CANCER YA QUE ES EFICAZ EN LA INHIBICION DEL CRECIMIENTO CELULAR ANORMAL.
GT200300287A 2002-12-19 2003-12-16 Complejos de e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino]quinazolin-6-il}alil)acetamida,suprocedimiento de produccion y uso GT200300287A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43470002P 2002-12-19 2002-12-19

Publications (1)

Publication Number Publication Date
GT200300287A true GT200300287A (es) 2004-11-30

Family

ID=32682089

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300287A GT200300287A (es) 2002-12-19 2003-12-16 Complejos de e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino]quinazolin-6-il}alil)acetamida,suprocedimiento de produccion y uso

Country Status (21)

Country Link
US (1) US20050075354A1 (es)
EP (1) EP1575936A1 (es)
JP (1) JP2006512355A (es)
KR (1) KR20050085835A (es)
CN (1) CN1726208A (es)
AR (1) AR042508A1 (es)
AU (1) AU2003283743A1 (es)
BR (1) BR0317259A (es)
CA (1) CA2509140A1 (es)
GT (1) GT200300287A (es)
MX (1) MXPA05006582A (es)
NL (1) NL1025072C2 (es)
NO (1) NO20052803L (es)
PA (1) PA8592501A1 (es)
PE (1) PE20040915A1 (es)
PL (1) PL377533A1 (es)
RU (1) RU2005122659A (es)
TW (1) TW200424191A (es)
UY (1) UY28129A1 (es)
WO (1) WO2004056802A1 (es)
ZA (1) ZA200504621B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
EP1896451A2 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Bicyclic derivatives for the treatment of abnormal cell growth
CA3024216C (en) † 2010-02-12 2021-03-30 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
EE200200710A (et) * 2000-06-22 2004-06-15 Pfizer Products Inc. Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks
MXPA04005157A (es) * 2001-11-30 2004-08-11 Pfizer Prod Inc Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
HUP0501069A2 (en) * 2001-12-12 2006-06-28 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production

Also Published As

Publication number Publication date
MXPA05006582A (es) 2005-08-16
EP1575936A1 (en) 2005-09-21
AR042508A1 (es) 2005-06-22
NL1025072C2 (nl) 2007-07-24
PE20040915A1 (es) 2005-01-18
ZA200504621B (en) 2006-03-29
PA8592501A1 (es) 2004-09-16
US20050075354A1 (en) 2005-04-07
JP2006512355A (ja) 2006-04-13
BR0317259A (pt) 2005-11-08
AU2003283743A1 (en) 2004-07-14
NL1025072A1 (nl) 2004-06-22
NO20052803D0 (no) 2005-06-09
PL377533A1 (pl) 2006-02-06
NO20052803L (no) 2005-09-16
UY28129A1 (es) 2004-07-30
WO2004056802A1 (en) 2004-07-08
RU2005122659A (ru) 2006-01-20
CN1726208A (zh) 2006-01-25
KR20050085835A (ko) 2005-08-29
TW200424191A (en) 2004-11-16
CA2509140A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
CR9929A (es) Nuevos compuestos
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
MY157661A (en) Bendamustine pharmaceutical compositions
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
TW200630374A (en) Thiazolyldihydroindazoles
ECSP056131A (es) Compuestos de carbonilo
CO6351786A2 (es) Inkibidores de la cinasa map p38
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
GT200300245A (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
UY28258A1 (es) Tratamiento terapeutico
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
ECSP055844A (es) Nuevos compuestos triciclicos
DOP2002000447A (es) 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5 onas como inhibidores de fosfodiesterasas
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
GT200300287A (es) Complejos de e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino]quinazolin-6-il}alil)acetamida,suprocedimiento de produccion y uso
CY1109187T1 (el) Νεα μακρολιδια
UA99707C2 (en) Phenanthridine derivatives as bradykinin antagonists
UY26847A1 (es) Derivados de la pirrolidina
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
UA86873C2 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
UY28115A1 (es) Derivados del acido isoftalico